Journal Mobile Options
Table of Contents
Vol. 76, Suppl. 3, 2011
Issue release date: September 2011
Horm Res Paediatr 2011;76(suppl 3):45–47
(DOI:10.1159/000330159)

Safety of Growth Hormone Treatment of Children with Idiopathic Short Stature: The US Experience

Allen D.B.
University of Wisconsin School of Medicine and Public Health and UW American Family Children’s Hospital, Madison, Wisc., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Recombinant human growth hormone (rhGH) is approved in the United States for treatment of idiopathic short stature (ISS). The occurrence of adverse events (AEs) and the long-term safety of rhGH treatment in this patient population are reviewed. Data were analyzed from postmarketing surveillance studies that included ISS patients, prospective ISS treatment trials and studies of specific AEs in smaller groups of rhGH-treated children. Frequency rates of targeted AEs (i.e., scoliosis, slipped capital femoral epiphysis, intracranial hypertension, pancreatitis) in patients with ISS are similar to or lower than the rates observed in other rhGH-treated conditions. At dosages of 0.24–0.37 mg/kg/week, rhGH treatment in children with ISS does not adversely affect blood glucose levels. At dosages ≧0.3 mg/kg/week, a dose-dependent increase in mean fasting and stimulated insulin levels is observed. Current evidence derived from ‘on-treatment’ surveillance studies suggests that rhGH does not increase the risk for new malignancies in children with ISS.The safety profile of rhGH at doses ≤0.37 mg/kg/week for the treatment of children with ISS is similar to or better than the profile seen in other rhGH-treated conditions and is not associated with any predictable AEs. Due to a continuing trend toward dose escalation to achieve greater height-promoting effects and the possibility of delayed post-treatment effects of hyperinsulinemia and/or heightened GH and insulin-like growth factor I exposure on cancer risk, caution and ongoing scrutiny of risks versus benefits are warranted.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Kemp SF, Kuntze J, Attie KM, Maneatis T, Butler S, Frane J, Lippe B: Efficacy and safety of long-term growth hormone treatment of idiopathic short stature. J Clin Endocrinol Metab 2005;90:5247–5253.
  2. Bell J, Parker KL, Swinford RD, Hoffman AR, Maneatis T, Lippe B: Long-term safety of recombinant human growth hormone in children. J Clin Endocrinol Metab 2010;95:167–177.
  3. Key L, Swinford R, Lippe B, Jacobs J, Alexander K, Connelly K, Maneatis T: Orthopedic adverse events (OAE) in children treated with recombinant human growth hormone (rhGH): National Cooperative Growth Study (NCGS). Lawson Wilkins Pediatric Endocrine Society/PAS Annual Meeting, Baltimore, Md., May 2009;2826.244.
  4. Quigley CA, Gill AM, Crowe BJ, Robling K, Chipman JJ, Rose SR, Ross JL, Cassorla FG, Wolka AM, Wit JM, Rekers-Mombarg LT, Cutler GB Jr: Safety of growth hormone treatment in pediatric patients with idiopathic short stature. J Clin Endocrinol Metab 2005;90:5188–5196.
  5. Bannink EMN, van der Palen RL, Mulder PG, de Muinck Keizer-Schrama SM: Long-term follow-up of GH-treated girls with Turner syndrome: metabolic consequences. Horm Res 2009;71:343–349.
  6. Lesage C, Walker J, Landier F, Chatelain P, Chaussain JL, Bougnères PF: Near-normalization of adolescent height with growth hormone therapy in very short children without growth hormone deficiency. J Pediatr 1991;119:29–34.
  7. Saenger P, Attie KM, Dimartino-Nardi J, Hintz R, Frahm L, Frane JW: Metabolic consequences of 5-year growth hormone therapy in children treated with GH for idiopathic short stature. Genentech Collaborative Study Group. J Clin Endocrinol Metab 1998;83:3115–3120.
  8. Heptulla RA, Boulware SD, Caprio S, Silver D, Sherwin RS, Tamborlane WV: Decreased insulin sensitivity and compensatory hyperinsulinemia after hormone treatment in children with short stature. J Clin Endocrinol Metab 1997;82:3234–3238.
  9. Swerdlow AJ, Higgins CD, Adlard P, Preece MA: Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959–85: a cohort study. Lancet 2002;360:273–277.
  10. Mills JL, Schonberger LB, Wysowski DK, Brown P, Durako SJ, Cox C, Kong F, Fradkin JE: Long-term mortality in the United States cohort of pituitary-derived growth hormone recipients. J Pediatr 2004;144:430–436.
  11. Allen DB, Rundle AC, Graves DA, Blethen SL: Risk of leukemia in children treated with human growth hormone: review and reanalysis. J Pediatr 1997;131:S32–S36.
  12. Nishi Y, Tanaka T, Takano K, Fujieda K, Igarashi Y, Hanew K, Hirano T, Yokoya S, Tachibana K, Saito T, Watanabe S: Recent status in the occurrence of leukemia in growth hormone-treated patients in Japan. GH Treatment Study Committee of the Foundation for Growth Science, Japan. J Clin Endocrinol Metab 1999;84:1961–1965.
  13. Tuffli GA, Johanson A, Rundle AC, Allen DB: Lack of increased risk for extracranial, nonleukemic neoplasms in recipients of recombinant deoxyribonucleic acid growth hormone. J Clin Endocrinol Metab 1995;80:1416–1422.
  14. Banerjee I, Clayton PE: Growth hormone treatment and cancer risk. Endocrinol Metab Clin North Am 2007;36:247–263.
  15. Cohen P, Rogol AD, Deal C, Saenger P, Reiter EO, Ross JL, Chernausek SD, Savage MO, Wit JM: 2007 ISS Consensus Workshop participants: Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. J Clin Endocrinol Metab 2008;93:4210–4217.


Pay-per-View Options
Direct payment This item at the regular price: USD 33.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 23.00